Pharmaceutical Executive August 2017

August 2017 | Volume 37, Issue 8
Pharmaceutical Executive August 2017
From the Editor
As more states approve the use of medical marijuana—and its rising profile as potential opioid alternative—industry and FDA are stepping up their focus on developing cannabis-derived therapies.
IFPMA's new Assistant Director General speaks about her mission to use the organization’s international reach to find real and practical solutions to the most pressing global healthcare challenges.
Experts assess the current pharma dealmaking landscape—one where, despite market headwinds, is still heavily influenced by factors under the buyer and seller’s control.
Pharm Exec’s 13th Annual Press Audit reveals a tonal undercurrent in sync with an industry unable to escape the glare of scrutiny.
For the life sciences industry in 2017, engaging across social media means less talking—and more listening. Peter Houston reports.
How artificial intelligence can help pharma filter out the online noise when monitoring for safety signals on the web.
Four strategic takeaways from this year's event that are important for pharma oncology leaders, by Maria Whitman and Sharon Karlsberg.
A review of the top contenders to land the agency as decision on its relocation draws closer.
The growing toll requires new assessment of risks, expanded provider education, and more scrutiny of marketed products.
Outlining the new communication priorities necessary to excel in the emerging outcomes-based healthcare landscape.
Special Sponsored Section
By Pharmaceutical Executive Editors
Indonesia, once considered by global investors as Asia’s “greatest underachiever,” is showing signs of an economic resurgence, nowhere more apparent than in the country’s pharmaceuticals sector.
lorem ipsum